FDA approval summary: capmatinib and tepotinib for the treatment of metastatic NSCLC harboring MET Exon 14 skipping mutations or alterations
[DOI] [PubMed] [Google Scholar] Commandeur J.N., Stijntjes G.J., Vermeulen N.P
Additionally, the mortality rate in the peptide subjects appeared to significantly decrease, with a 2-fold decrease in the Thymalin subjects, a 1.8-fold decrease in the Epithalon subjects, and 2.5-fold decrease in the subjects presented with both peptides
Practitioners also carefully screen patients: for example, they check for metal allergies (since GHK-Cu contains copper) and discuss alternative evidence-based treatments
This distinction matters because the best peptide depends on the goal
doi: 10.1038/srep37664 (2016)